|
Wed, 12/11/2019 - 23:16 |
Roches fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer |
Rocheusa |
|
Wed, 12/05/2018 - 10:22 |
Roches Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment |
Rocheusa |
|
Wed, 12/05/2018 - 01:46 |
Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint |
American Associ... |
|
Tue, 12/04/2018 - 23:19 |
Genentechs Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment |
Genentech |
|
Wed, 10/17/2018 - 05:43 |
Roche reports very strong growth in the first nine months of 2018 |
Rocheusa |
|
Mon, 10/15/2018 - 05:02 |
Roches Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment |
Rocheusa |
|
Sun, 10/14/2018 - 17:56 |
Genentechs Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment |
Genentech |
|
Fri, 06/01/2018 - 11:34 |
European Commission approves Roches Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence |
Rocheusa |
|
Fri, 04/27/2018 - 09:12 |
CHMP recommends EU approval of Roches Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence |
Rocheusa |
|
Wed, 04/25/2018 - 21:03 |
Roche reports a strong start in 2018 |
Rocheusa |
|
Thu, 02/01/2018 - 00:34 |
Roche reports good results in 2017 |
Rocheusa |
|
Wed, 01/24/2018 - 23:48 |
Emerging Areas in Chemotherapy, Hormone Therapy and Targeted Therapy |
Susan G Komen |
|
Wed, 12/20/2017 - 23:01 |
FDA approves Roches Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer |
Rocheusa |
|
Wed, 12/20/2017 - 11:18 |
FDA Approves Genentechs Perjeta (Pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer |
Genentech |
|
Wed, 10/25/2017 - 03:29 |
Filed for Additional Indication of Adjuvant Therapy for HER2-Positive Early Breast Cancer |
Chugai |
|
Wed, 10/18/2017 - 22:24 |
Roche reports strong sales growth in the first nine months of 2017 |
Rocheusa |
|
Thu, 09/28/2017 - 20:12 |
FDA grants Priority Review for Roches Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer |
Rocheusa |
|
Thu, 09/28/2017 - 01:48 |
FDA Grants Priority Review for Genentechs Perjeta (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer |
Genentech |
|
Wed, 07/26/2017 - 22:54 |
Roche reports strong performance in the first half of 2017 |
Rocheusa |
|
Mon, 06/05/2017 - 05:25 |
Researchers Find Drug Combination Reduces Recurrence Risk in Patients with HER2-Positive Early Breast Cancer |
MSKCC |
|
Mon, 06/05/2017 - 04:27 |
APHINITY study shows Roches Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer |
Rocheusa |
|
Mon, 06/05/2017 - 03:13 |
APHINITY Study Shows Genentechs Perjeta-Based Regimen Reduced the Risk of Invasive Cancer Returning Compared to Herceptin and Chemotherapy in HER2-Positive Early Breast Cancer |
Genentech |
|
Thu, 05/11/2017 - 01:55 |
Roche to present new data on personalised medicines and cancer immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting |
Rocheusa |
